

Arch Therapeutics, Inc.  
Form 8-K  
August 06, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 6, 2014**

**ARCH THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

<b>Nevada</b>	<b>000-54986</b>	<b>46-0524102</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

<b>20 William Street, Suite 270</b>	
<b>Wellesley, Massachusetts</b>	<b>02481</b>
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(617) 431-2313**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: Arch Therapeutics, Inc. - Form 8-K

“Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

“Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

“Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

**Item 7.01 Regulation FD Disclosure.**

The information in this Current Report, including the exhibits attached hereto, is furnished pursuant to Item 2.02 – “Results of Operations and Financial Condition” and Item 7.01 - “Regulation FD Disclosure” of Form 8-K, and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “**Securities Act**”), or the Exchange Act regardless of any general incorporation language in such filing.

On August 6, 2014, Arch Therapeutics, Inc. (the “**Company**”) issued a press release announcing its financial results for the quarter ended June 30, 2014. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibit**

(d) Exhibits

**Exhibit Description**

99.1 Press Release issued by Arch Therapeutics, Inc. on August 6, 2014\*

\* This exhibit is intended to be furnished and shall not be deemed “filed” for purposes of the Exchange Act

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ARCH THERAPEUTICS, INC.**

Dated: August 6, 2014 By: /s/ Terrence W. Norchi, M.D.  
Name: Terrence W. Norchi, M.D.  
Title: President, Chief Executive  
Officer

EXHIBIT INDEX

**Exhibit Description**

99.1 Press Release issued by Arch Therapeutics, Inc. on August 6, 2014\*

\* This exhibit is intended to be furnished and shall not be deemed “filed” for purposes of the Exchange Act